Allergan announced the launch of the new Liletta (levonorgestrel-releasing intrauterine system) 52 mg IUD single-handed inserter (intrauterine device), for use...
Objectives: Safe and effective contraceptive options for obese women are becoming more important due to the obesity epidemic within the...
Allergan has announced that the U.S. FDA has accepted for filing the company's supplemental New Drug Application (sNDA) to potentially...
Medicines360/Allergan announced newly published data finding that Liletta (levonorgestrel releasing intrauterine system) is highly efficacious in preventing pregnancy over five...
Bayer HealthCare has successfully concluded the European registration procedure for its new low dose levonorgestrel-releasing intrauterine system (IUS) called Jaydress....
The FDA has approved a new low-dose hormone intrauterine device designed to prevent pregnancy, the first new device of its...
Medicines360 presented new six-year data from the ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), Liletta (levonorgestrel-releasing...
Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced that the FDA has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.
Contraception for up to 5 years.
Bayer has announced that the supplemental New Drug Application (sNDA) for the extended use up to eight years in the indication, contraception was approved for its levonorgestrel (LNG) releasing intrauterine system (IUS) Mirena by the FDA.